On June 30, 2026, AC Immune SA announced 12-month data from the Phase 1b/2 ABATE Trial evaluating ACI-24 for the treatment of Prodromal Alzheimer’s Disease. The company operates in the biotechnology industry and develops immunotherapies for neurodegenerative diseases.

AC Immune SA announced on June 11, 2026, that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This funding will support the extension of Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, an anti-alpha-synuclein active immunotherapy for early Parkinson's disease. AC Immune SA is a biotechnology company focused on developing immunotherapy-based solutions for neurodegenerative diseases.